You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR QUIZARTINIB DIHYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for quizartinib dihydrochloride

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00462761 ↗	A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status	Completed	Daiichi Sankyo Inc.	Phase 1	2007-01-01	Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
NCT00462761 ↗	A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status	Completed	Daiichi Sankyo, Inc.	Phase 1	2007-01-01	Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
NCT01390337 ↗	A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)	Completed	Ambit Biosciences Corporation	Phase 1	2011-10-01	The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
NCT01390337 ↗	A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)	Completed	Daiichi Sankyo Inc.	Phase 1	2011-10-01	The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
NCT01390337 ↗	A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)	Completed	Daiichi Sankyo, Inc.	Phase 1	2011-10-01	The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
NCT01411267 ↗	AC220 for Children With Relapsed/Refractory ALL or AML	Completed	Ambit Biosciences Corporation	Phase 1	2011-09-01	This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for quizartinib dihydrochloride

Condition Name

Chart
Table

Condition Name for quizartinib dihydrochloride
Intervention	Trials
Acute Myeloid Leukemia	11
Leukemia, Myeloid, Acute	6
Recurrent Acute Myeloid Leukemia	5
Recurrent Myelodysplastic Syndrome	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for quizartinib dihydrochloride
Intervention	Trials
Leukemia, Myeloid, Acute	23
Leukemia	23
Leukemia, Myeloid	22
Preleukemia	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for quizartinib dihydrochloride

Trials by Country

Map
Table

Trials by Country for quizartinib dihydrochloride
Location	Trials
United States	117
Spain	19
Japan	16
Canada	8
United Kingdom	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for quizartinib dihydrochloride
Location	Trials
Texas	17
California	8
New York	7
Illinois	6
Pennsylvania	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for quizartinib dihydrochloride

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for quizartinib dihydrochloride
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	8
Phase 1/Phase 2	9
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for quizartinib dihydrochloride
Clinical Trial Phase	Trials
Completed	14
Recruiting	13
Active, not recruiting	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for quizartinib dihydrochloride

Sponsor Name

Chart
Table

Sponsor Name for quizartinib dihydrochloride
Sponsor	Trials
Daiichi Sankyo, Inc.	11
National Cancer Institute (NCI)	7
Daiichi Sankyo Co., Ltd.	7
[disabled in preview]	18
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for quizartinib dihydrochloride
Sponsor	Trials
Industry	35
Other	20
NIH	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.